New president named at Allergan


The board of directors of Inc. has Douglas S. Ingram as of the company. In this newly established role, Ingram will report directly to CEO and chairman David Pyott and will lead the company’s global commercial operations, with responsibility for Allergan’s portfolio of pharmaceutical, consumer and medical device products including ophthalmology products such as Restasis, Lumigan, Alphagan, Combigan, Ganfort, Optive, and Ozurdex; facial aesthetics products such as Botox Cosmetic and the Juvederm family of facial fillers; and Botox for therapeutic uses, which has been approved in more than 85 countries to treat 26 different conditions such as spasticities, dystonias, chronic migraine, and the urological conditions of neurogenic detrusor overactivity and idiopathic overactive bladder; and medical dermatology products such as Aczone. Ingram will begin transitioning to this new role immediately.

“During his 17-year tenure at Allergan, Doug has consistently demonstrated leadership and high performance across many segments of our business,” Pyott says. “Doug has built an impressive record of accomplishment and is widely regarded throughout our organization as a leader who is committed to the highest standards of excellence in all areas. I am confident that his broad range of commercial and functional experiences will serve him well as he assumes this new and important role.”

With more than 25 years of professional experience, Ingram has a significant background in the healthcare industry, both in the United States and internationally. For the past three years, Ingram has served as executive VP and president, Europe, Africa and Middle East (EAME) for Allergan. In this role, he was responsible for the company’s regional pharmaceutical and medical device operations, with a focus on strategic planning, sales and marketing, development, and general management.

Prior to leading the EAME region, Ingram served as executive VP and…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS